BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-650-8895020
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date12/5/2019 (Estimated)
OptionableNot Optionable
Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions
What is Biopharmx's stock symbol?
Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."
When did Biopharmx's stock split? How did Biopharmx's stock split work?
Biopharmx shares reverse split before market open on Friday, April 26th 2019. The 1-25 reverse split was announced on Monday, April 15th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 25th 2019. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 4 shares after the split.
How were Biopharmx's earnings last quarter?
Biopharmx Corp (NYSEAMERICAN:BPMX) released its earnings results on Monday, September, 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.34) by $0.12. View Biopharmx's Earnings History.
When is Biopharmx's next earnings date?
What price target have analysts set for BPMX?
1 brokers have issued 1-year price objectives for Biopharmx's shares. Their forecasts range from $1.00 to $1.00. On average, they expect Biopharmx's share price to reach $1.00 in the next year. This suggests a possible upside of 170.3% from the stock's current price. View Analyst Price Targets for Biopharmx.
What is the consensus analysts' recommendation for Biopharmx?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biopharmx.
Has Biopharmx been receiving favorable news coverage?
Media headlines about BPMX stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Biopharmx earned a daily sentiment score of -1.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Biopharmx.
Are investors shorting Biopharmx?
Biopharmx saw a increase in short interest in August. As of August 31st, there was short interest totalling 334,700 shares, an increase of 44.4% from the July 31st total of 231,800 shares. Based on an average daily trading volume, of 877,900 shares, the short-interest ratio is currently 0.4 days. Currently, 3.3% of the company's shares are short sold. View Biopharmx's Current Options Chain.
Who are some of Biopharmx's key competitors?
Some companies that are related to Biopharmx include Ibio (IBIO), Fusion Antibodies (FAB), Trillium Therapeutics (TRIL), Immuron (IMC), Hvivo (HVO), Briacell Therapeutics (BCT), Realm Therapeutics (RLM), Bioxyne (BXN), Rezolute (RZLT), Naturally Splendid Enterprises (NSP), Anatara Lifesciences (ANR), Kane Biotech (KNE), e-Therapeutics (ETX), Redx Pharma (REDX) and Living Cell Technologies (LCT).
What other stocks do shareholders of Biopharmx own?
Who are Biopharmx's key executives?
Biopharmx's management team includes the folowing people:
- Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
- Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
- Dr. José Zayas, Sr. VP of Operations
- Ms. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)
- Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs
Who are Biopharmx's major shareholders?
Biopharmx's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vivo Capital LLC (3.03%), Vanguard Group Inc. (0.75%) and Nadler Financial Group Inc. (0.52%). Company insiders that own Biopharmx stock include Anja B Krammer, David S Tierney, Stephen Morlock and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Biopharmx.
Which major investors are selling Biopharmx stock?
BPMX stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC and Vanguard Group Inc.. Company insiders that have sold Biopharmx company stock in the last year include Anja B Krammer, Stephen Morlock and Vivo Capital Viii, Llc. View Insider Buying and Selling for Biopharmx.
Which major investors are buying Biopharmx stock?
BPMX stock was purchased by a variety of institutional investors in the last quarter, including Nadler Financial Group Inc.. Company insiders that have bought Biopharmx stock in the last two years include David S Tierney and Stephen Morlock. View Insider Buying and Selling for Biopharmx.
How do I buy shares of Biopharmx?
Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Biopharmx's stock price today?
One share of BPMX stock can currently be purchased for approximately $0.37.
How big of a company is Biopharmx?
What is Biopharmx's official website?
How can I contact Biopharmx?
Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.
MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
